Investigational drug · Phase 2
CBX-12
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
5
Any phase or sponsor naming "CBX-12"
First trial start
2021
May 3, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CBX-12", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor, Adult
- Epithelial Ovarian Cancer
- Small Cell Lung Carcinoma
- Breast Cancer
- Colorectal Cancer
- Pancreas Cancer
- Appendix Cancer
- Non-small Cell Lung Cancer
- Gastric Cancer
- Esophagus Cancer
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Ovarian cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "CBX-12" as an intervention, largest first.
- A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to TreatNot yet recruiting
Children's Oncology GroupResearch network
NCT07830667 · 79 participants (planned) · Start May 7, 2027 · Primary completion Jun 30, 2033
Drug: pH Low Insertion Peptide-exatecan Conjugate CBX-12 · For: Recurrent Childhood Ewing Sarcoma; Recurrent Childhood Malignant Solid Neoplasm; Recurrent Childhood Rhabdomyosarcoma and 9 more
Cybrexa TherapeuticsIndustry
NCT04902872 · 69 participants · Start May 3, 2021 · Primary completion Jun 24, 2025
Drug: CBX-12 · For: Solid Tumor, Adult; Epithelial Ovarian Cancer; Small Cell Lung Carcinoma and 9 more
Sites: New Haven, Connecticut; Austin, Texas; Houston, Texas · 4 sites in all
Cybrexa TherapeuticsIndustry
NCT06315491 · 40 participants · Start Sep 25, 2024 · Primary completion Oct 31, 2025
Drug: CBX-12 · For: Platinum-resistant Ovarian Cancer; Refractory Ovarian Carcinoma
Sites: Tucson, Arizona
- CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal CancerActive, not recruiting
National Cancer Institute (NCI)NIH
NCT06730100 · 35 participants (planned) · Start Sep 11, 2025 · Primary completion Dec 1, 2026
Drug: pH Low Insertion Peptide-exatecan Conjugate CBX-12 · For: Metastatic Mismatch Repair Proficient Colorectal Carcinoma; Refractory Mismatch Repair Proficient Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8
Sites: Irvine, California; Los Angeles, California; Orange, California · 15 sites in all
National Cancer Institute (NCI)NIH
NCT05691517 · 35 participants (planned) · Start Jun 12, 2024 · Primary completion Oct 15, 2028
Drug: pH Low Insertion Peptide-exatecan Conjugate CBX-12 · For: Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm
Sites: Bethesda, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- Peptide-Drug Conjugates: A New Hope for Cancer.
Armstrong A, Coburn F, Nsereko Y, et al. · J Pept Sci 2025
- Antigen-independent tumor targeting by CBX-12 (alphalexࡊ-exatecan) induces long-term antitumor immunity.
Gayle S, Paradis T, Jones K, et al. · Immunotherapy 2022
- TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor.
Jo U, Murai Y, Agama KK, et al. · Mol Cancer Ther 2022
Also in development for Solid Tumor, Adult
- VisugromabCTL-002, Visugromab RDEPhase 36 trials
CatalYm GmbH · Adult Solid Tumor, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Unresectable or Metastatic Hepatocellular Carcinoma
- anzutresgene autoleucelIMA203 Product, IMA203 product- flat dosePhase 32 trials
Immatics US, Inc. · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
- CRB-701Phase 32 trials
Corbus Pharmaceuticals Inc. · Solid Tumor, Adult, Oropharyngeal Carcinoma (OPC)
- HMPL-453Phase 32 trials
Hutchmed · Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult, Solid Tumor
- VT3989Phase 32 trials
Vivace Therapeutics, Inc · Pleural Mesothelioma, Mesothelioma, Solid Tumor, Adult
- DabogratinibTYRA-300Phase 24 trials
Tyra Biosciences, Inc · FGFR3 Gene Mutation, FGFR3 Gene Alteration, Achondroplasia
- VS-7375Phase 24 trials
Verastem, Inc. · G12D Mutated KRAS, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
- Tmod CAR T-cell TherapyA2B530, A2B694Phase 23 trials
A2 Biotherapeutics Inc. · Solid Tumor, Adult, Colorectal Cancer, Colorectal Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.